These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36547953)

  • 1. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
    Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
    JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
    Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
    Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.
    Maid PJ; Xavier R; Real RM; Pedersen R; Shen Q; Marshall L; Solano G; Borlenghi CE; Hidalgo RP
    J Clin Rheumatol; 2018 Jun; 24(4):177-182. PubMed ID: 29232322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 5. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
    Colman RJ; Portocarrero-Castillo A; Chona D; Hellmann J; Minar P; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):507-515. PubMed ID: 32426829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidrug antibodies in psoriasis: a systematic review.
    Hsu L; Snodgrass BT; Armstrong AW
    Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
    Fabiani C; Vitale A; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Capozzoli M; Fusco F; Rana F; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Jan; 38(1):63-70. PubMed ID: 29611087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory.
    Keating PE; Hock BD; Chin PKL; O'Donnell JL; Barclay ML
    Ther Drug Monit; 2024 Oct; 46(5):619-626. PubMed ID: 38648648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
    Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
    Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY; Lee Y; Choe BH; Kang B
    Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
    JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation.
    Karsten C; Grannas K; Bergman O; Movérare R; Roforth M; Willrich MAV; Snyder MR; Yang YK
    AAPS J; 2024 Jul; 26(5):86. PubMed ID: 39044059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.
    Liu W; Bai D; Kou L
    BMC Ophthalmol; 2023 May; 23(1):240. PubMed ID: 37248486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays.
    Vroemen WHM; Agata SS; van Beers JJBC; Damoiseaux JGMC
    Antibodies (Basel); 2024 Sep; 13(3):. PubMed ID: 39311378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
    Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
    Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.